EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety

Khuram W Chaudhary iD, Colleen E Clancy iD, Pei-Chi Yang iD, Jennifer B Pierson iD, Alan L Goldin iD, John E Koerner, Todd A Wisialowski iD, Jean-Pierre Valentin iD, John P Imredy iD, Armando Lagrutta iD, Simon Authier iD, Robert Kleiman iD und 3 weitere

Clinical and Translational Science · 2024-12 · 17 (12)

DOI: 10.1111/cts.70098 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 11.12.2024. Verfasst von Khuram W Chaudhary und 14 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: NAV1.5 Voltage-Gated Sodium Channel, Action Potentials. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The human voltage‐gated sodium channel Na v 1.5 (hNa v 1.5/SCN5A) plays a critical role in the initiation and propagation of action potentials in cardiac myocytes, and its modulation by various drugs has significant implications for cardiac safety. Drug‐dependent block of Na v 1.5 current (I Na ) can lead to significant alterations in cardiac electrophysiology, potentially resulting in conduction slowing and an increased risk of proarrhythmic events. This review aims to provide a comprehensive overview of the mechanisms by which various pharmacological agents interact with Na v 1.5, focusing on the molecular determinants of drug binding and the resultant electrophysiological effects. We discuss the structural features of Na v 1.5 that influence drug affinity and specificity. Special attention is given to the concept of state‐dependent block, where drug binding is influenced by the conformational state of the channel, and its relevance to therapeutic efficacy and safety. The review also examines the clinical implications of I Na block, highlighting case studies of drugs that have been associated with adverse cardiac events, and how the Vaughan‐Williams Classification system has been employed to qualify “unsafe” sodium channel block. Furthermore, we explore the methodologies currently used to assess I Na block in nonclinical and clinical settings, with the hope of providing a weight of evidence approach including in silico modeling, in vitro electrophysiological assays and in vivo cardiac safety studies for mitigating proarrhythmic risk early in drug discovery. This review underscores the importance of understanding Na v 1.5 pharmacology in the context of drug development and cardiac risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NAV1.5 Voltage-Gated Sodium ChannelAction PotentialsHumansMyocytes, CardiacAnimalsHeart Conduction SystemArrhythmias, CardiacVoltage-Gated Sodium Channel BlockersSodium Channel Blockers

Substanzen

NAV1.5 Voltage-Gated Sodium ChannelSCN5A protein, humanVoltage-Gated Sodium Channel BlockersSodium Channel Blockers

Autor:innen und Institutionen

  • Bristol Myers Squibb, New Brunswick, New Jersey, USA.
  • Department of Physiology and Membrane Biology, University of California Davis, Davis, California, USA.
  • HESI, Washington, DC, USA.
  • University of California, Irvine, Irvine, California, USA.
  • Independent, San Diego, California, USA.
  • Pfizer, Groton, Connecticut, USA.

ORCID-Profile: Khuram W Chaudhary, Colleen E Clancy, Pei-Chi Yang, Jennifer B Pierson, Alan L Goldin, Todd A Wisialowski, Jean-Pierre Valentin, John P Imredy, Armando Lagrutta, Simon Authier, Robert Kleiman, Philip T Sager, Peter Hoffmann, Michael K Pugsley

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Chaudhary, K. W., Clancy, C. E., Yang, P. C., Pierson, J. B., Goldin, A. L., Koerner, J. E., Wisialowski, T. A., Valentin, J. P., Imredy, J. P., Lagrutta, A., Authier, S., Kleiman, R., Sager, P. T., Hoffmann, P., & Pugsley, M. K. (2024). An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety. Clinical and Translational Science, 17(12). https://doi.org/10.1111/cts.70098

Vancouver

Chaudhary KW, Clancy CE, Yang PC, Pierson JB, Goldin AL, Koerner JE, et al. An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety. Clinical and Translational Science. 2024;17(12). doi:10.1111/cts.70098

BibTeX
@article{Chaudhary2024,
  author = {Chaudhary, Khuram W and Clancy, Colleen E and Yang, Pei-Chi and Pierson, Jennifer B and Goldin, Alan L and Koerner, John E and Wisialowski, Todd A and Valentin, Jean-Pierre and Imredy, John P and Lagrutta, Armando and Authier, Simon and Kleiman, Robert and Sager, Philip T and Hoffmann, Peter and Pugsley, Michael K},
  title = {An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {12},
  doi = {10.1111/cts.70098}
}
Kostenlos starten →